Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
Stories About 1093.HK
CSPC has unveiled a record licensing deal with AstraZeneca

Big deal, bigger doubts: CSPC slides after $18.5 billion pact

2026-02-12
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

2025-11-27
CSPC Pharma teases big bucks deals after earnings miss

CSPC Pharma teases big bucks deals after earnings miss

2025-06-12
Earnings blow for CSPC Pharma

Earnings blow for CSPC Pharma as the state drives a hard bargain

2025-03-06

BRIEF: CSPC Pharma profit dips on falling drug revenue

2024-11-01
CSPC develops, produces and sells its own innovative drugs. Its growth has been sluggish over the past three years due to a slowdown for its finished drug business.

FAST NEWS: CSPC Pharma’s urticaria drug approved in China

2024-10-09
Liu Yongjun’s experience in the commercialization of innovative drugs and his connections with multinational pharmaceutical companies are urgently needed for CSPC Pharmaceutical’s ongoing transformation.

CSPC Pharma taps R&D superstar in quest for new breakout drugs

2024-09-19
CSPC Pharma weighs up diet drug for bigger bottom line

CSPC Pharma weighs up diet drug for bigger bottom line

2024-06-05

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

2023-03-29

Recent Articles

Illustration of Starbucks China's new policy to clear non-paying loiterers
October 28, 2026

Starbucks clears its China tables, as the robotics bubble quietly deflates

SBUX.US
2670.HK
October 28, 2026

Electronic materials growth lifts Red Avenue’s nine-month profit 5.7%

9607.HK
603650.SHG
October 28, 2026

Dongshan Precision flat in Hong Kong trading debut

2384.HK
002384.SHE
October 28, 2026

Pop Mart’s bubble bursts with fading Labubu craze

9992.HK
October 28, 2026

Forex losses smudge Fuyao’s profit, as smart glass awaits volume growth

3606.HK
600660.SHG
October 27, 2026

SPONSORED: KLN and Maxim’s: Growing Together for Nearly a Decade

October 27, 2026

New product sales drive Nexchip’s revenue up nearly 20% in third quarter

2249.HK
688249.SHG

RELATED ARTICLES

No related posts.

Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2026 Bamboo Works. All rights reserved.